Mirum says Phase 3 AZURE-1 trial meets primary endpoint for brelovitug in chronic hepatitis delta virus
Bitget2026/09/28 12:03- Mirum reported Phase 3 AZURE-1 met its primary endpoint for brelovitug in chronic hepatitis delta at Week 24.
- Results showed the drug improved viral control and liver inflammation versus delayed treatment, supporting its potential as a single-agent therapy.
- Longer-term Phase 2b data through Week 48 showed responses continued to strengthen with extended dosing.
- Full Phase 3 results will be presented at a future medical congress; AZURE-4 topline data are expected in Q4 2026.
- Planning a U.S. BLA submission in H1 2027; targeting a potential U.S. launch in Q4 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The British Pound rallies on a UK growth upgrade and gives more than half back
Only twice in history! S&P 500 equal-weight index is expected to record seven consecutive weeks of decline this week
The S&P 500 Equal Weight Index is expected to fall for a seventh consecutive week. If this downward trend continues through Friday, it will mark only the third time in history that the index has experienced seven straight weeks of decline.
Trump “bites” Powell, demanding his resignation from the Federal Reserve Board, citing severe cost overruns in headquarters renovation.
U.S. President Trump on Wednesday called for former Federal Reserve Chairman Powell to resign from his position as a Fed governor, following an inspector general report on the Federal Reserve headquarters renovation project, which highlighted a series of management issues that led to significant cost overruns.
Crypto prices
More
